{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:32:36Z","timestamp":1790735556585,"version":"4.1.0"},"reference-count":109,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG19862"],"award-info":[{"award-number":["IG19862"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Breast cancer (BC) is the most frequent oncologic cause of death among women and the improvement of its treatments is compelling. Platinum salts (e.g., carboplatin, cisplatin, and oxaliplatin) are old drugs still used to treat BC, especially the triple-negative subgroup. However, only a subset of patients see a concrete benefit from these drugs, raising the question of how to select them properly. Therefore, predictive biomarkers for platinum salts in BC still represent an unmet clinical need. Here, we review clinical and preclinical works in order to summarize the current evidence about predictive or putative platinum salt biomarkers in BC. The association between BRCA1\/2 gene mutations and platinum sensitivity has been largely described. However, beyond the mutations of these two genes, several other proteins belonging to the homologous recombination pathways have been linked to platinum response, defining the concept of BRCAness. Several works, here reviewed, have tried to capture BRCAness through different strategies, such as homologous recombination deficiency (HRD) score and genetic signatures. Moreover, p53 and its family members (p63 and p73) might also be used as predictors of platinum response. Finally, we describe the mounting preclinical evidence regarding base excision repair deficiency as a possible new platinum biomarker.<\/jats:p>","DOI":"10.3390\/ijms20143390","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T11:56:51Z","timestamp":1562759811000},"page":"3390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors"],"prefix":"10.3390","volume":"20","author":[{"given":"Mattia","family":"Garutti","sequence":"first","affiliation":[{"name":"U.O.C Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy"},{"name":"Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pelizzari","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"},{"name":"Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"},{"name":"Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde Clarissa","family":"Malfatti","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-4834","authenticated-orcid":false,"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"},{"name":"Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-6448","authenticated-orcid":false,"given":"Gianluca","family":"Tell","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"},{"name":"Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pathol.2016.10.012","article-title":"Molecular classification of breast cancer: What the pathologist needs to know","volume":"49","author":"Rakha","year":"2017","journal-title":"Pathology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2016.06.004","article-title":"Do platinum salts fit all triple negative breast cancers?","volume":"48","author":"Gerratana","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10549-016-4025-3","article-title":"Platinum salts in advanced breast cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"160","author":"Petrelli","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: An intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers"},{"key":"ref_10","first-page":"21","article-title":"Effects of cisplatin on dna and the possible relationships to cytotoxicity and mutagenicity in mammalian cells","volume":"73","author":"Zwelling","year":"2013","journal-title":"Cisplatin"},{"key":"ref_11","unstructured":"Rosenberg, B. (2013). Cisplatin: Its history and possible mechanisms of action. Cisplatin, Academic Press."},{"key":"ref_12","unstructured":"Bradner, W.T., Rose, W.C., and Huftalen, J.B. (2013). antitumor activity of platinum analogs. Cisplatin, Academic Press."},{"key":"ref_13","first-page":"929","article-title":"Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells","volume":"55","author":"Cui","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_14","first-page":"1312","article-title":"Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance","volume":"60","author":"Komatsu","year":"2000","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/mol.104.001198","article-title":"The Copper Influx Transporter Human Copper Transport Protein 1 Regulates the Uptake of Cisplatin in Human Ovarian Carcinoma Cells","volume":"66","author":"Holzer","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00280-003-0736-3","article-title":"Cross-resistance to cisplatin in cells with acquired resistance to copper","volume":"53","author":"Safaei","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_17","first-page":"6559","article-title":"Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper","volume":"62","author":"Katano","year":"2002","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0009-2797(87)90004-4","article-title":"Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes","volume":"61","author":"Eastman","year":"1987","journal-title":"Chem. Biol. Interact."},{"key":"ref_20","first-page":"3237","article-title":"Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin","volume":"51","author":"Kasahara","year":"1991","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.59.4.657","article-title":"Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?","volume":"59","author":"Gonzalez","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.toxlet.2013.11.015","article-title":"Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation","volume":"225","author":"Becker","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1093\/nar\/23.19.3810","article-title":"Strategic down-regulation of DNA polymerase \u03b2 by antisense RNA sensitizes mammalian cells to specific DNA damaging agents","volume":"23","author":"Horton","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kelley, M.R., Jiang, Y., Guo, C., Reed, A., Meng, H., and Vasko, M.R. (2014). Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106485"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mrfmmm.2015.06.010","article-title":"APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER","volume":"779","author":"Kim","year":"2015","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14564","DOI":"10.1074\/jbc.M111.225375","article-title":"Novel role of base excision repair in mediating cisplatin cytotoxicity","volume":"286","author":"Kothandapani","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7332","DOI":"10.1093\/nar\/gkt479","article-title":"Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity","volume":"41","author":"Kothandapani","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1091\/mbc.e13-12-0717","article-title":"Nucleophosmin modulates stability, activity, and nucleolar accumulation of base excision repair proteins","volume":"25","author":"Poletto","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1158\/1535-7163.MCT-08-0929","article-title":"Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2\u2032-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs","volume":"8","author":"Preston","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dnarep.2017.01.002","article-title":"Differential role of base excision repair proteins in mediating cisplatin cytotoxicity","volume":"51","author":"Sawant","year":"2017","journal-title":"DNA Repair"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1093\/nar\/gky764","article-title":"Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage","volume":"46","author":"Slyskova","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/onc.2009.327","article-title":"Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy","volume":"29","author":"Yang","year":"2010","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","article-title":"Repair Pathway Choices and Consequences at the Double-Strand Break","volume":"26","author":"Ceccaldi","year":"2016","journal-title":"Trends Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4161\/cc.7.18.6679","article-title":"DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1093\/nar\/gks270","article-title":"Homologous recombination and its regulation","volume":"40","author":"Krejci","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"a012740","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of Strand Breaks by Homologous Recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1139\/bcb-2016-0012","article-title":"Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication","volume":"94","author":"Godin","year":"2016","journal-title":"Biochem. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","article-title":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: Implications for hereditary breast and\/or ovarian cancer syndrome testing","volume":"145","author":"Sharma","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.dnarep.2004.03.022","article-title":"Structure and function of the double-strand break repair machinery","volume":"3","author":"Shin","year":"2004","journal-title":"DNA Repair"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0092-8674(00)80503-6","article-title":"Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage","volume":"90","author":"Scully","year":"1997","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic Complete Response Rates in Young Women with BRCA1-Positive Breast Cancers after Neoadjuvant Chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy with Biomarker Assessment in Metastatic Triple-Negative Breast Cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdy201","article-title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: Results from the tnAcity trial","volume":"29","author":"Yardley","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the Addition of Carboplatin and\/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response\u2014Final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial","volume":"15","author":"Schneeweiss","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S2-05","DOI":"10.1158\/1538-7445.SABCS15-S2-05","article-title":"Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +\/-carboplatin and\/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)","volume":"76","author":"Sikov","year":"2016","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1158\/1538-7445.SABCS15-P3-07-12","article-title":"Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis","volume":"76","author":"Telli","year":"2016","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","article-title":"Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","volume":"151","author":"Kaklamani","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/annonc\/mdx821","article-title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)","volume":"29","author":"Sharma","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdt306","article-title":"BRCAness: A deeper insight into basal-like breast tumors","volume":"24","author":"Pinto","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/jco.2015.33.15_suppl.1004","article-title":"Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto","volume":"33","author":"Timms","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.31898","article-title":"BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy","volume":"144","author":"Mio","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/bcr1649","article-title":"Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers","volume":"9","author":"Jumppanen","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/bcr1517","article-title":"Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients","volume":"8","author":"Calza","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers?","volume":"123","author":"Bertucci","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000455820","article-title":"Biological Subtypes of Triple-Negative Breast Cancer","volume":"12","author":"Hubalek","year":"2017","journal-title":"Breast Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMoa052933","article-title":"Concordance among Gene-Expression\u2013Based Predictors for Breast Cancer","volume":"355","author":"Fan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","article-title":"Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype","volume":"14","author":"Cheang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Marcel, V., Nguyen Van Long, F., and Diaz, J.-J. (2018). 40 Years of Research Put p53 in Translation. Cancers, 10.","DOI":"10.3390\/cancers10050152"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","article-title":"Mutant p53 as a guardian of the cancer cell","volume":"26","author":"Mantovani","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/mol.57.3.503","article-title":"Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line","volume":"57","author":"Pestell","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","article-title":"High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer","volume":"69","author":"Holstege","year":"2009","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.yexcr.2012.01.023","article-title":"p63\/p73 in the control of cell cycle and cell death","volume":"318","author":"Allocati","year":"2012","journal-title":"Exp. Cell Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2005.12.013","article-title":"p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis","volume":"9","author":"Rocco","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI30866","article-title":"The p63\/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers","volume":"117","author":"Leong","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.dnarep.2017.06.007","article-title":"BERing the burden of damage: Pathway crosstalk and posttranslational modification of base excision repair proteins regulate DNA damage management","volume":"56","author":"Limpose","year":"2017","journal-title":"DNA Repair"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1093\/nar\/gkt076","article-title":"Mammalian base excision repair: The forgotten archangel","volume":"41","author":"Dianov","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Antoniali, G., Malfatti, M.C., and Tell, G. (2017). Unveiling the non-repair face of the Base Excision Repair pathway in RNA processing: A missing link between DNA repair and gene expression?. DNA Repair.","DOI":"10.1016\/j.dnarep.2017.06.008"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.dnarep.2003.09.002","article-title":"Orchestration of base excision repair by controlling the rates of enzymatic activities","volume":"3","author":"Allinson","year":"2004","journal-title":"DNA Repair"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.dnarep.2007.01.009","article-title":"A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification","volume":"6","author":"Almeida","year":"2007","journal-title":"DNA Repair"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.dnarep.2006.12.009","article-title":"Twists and turns in the function of DNA damage signaling and repair proteins by post-translational modifications","volume":"6","author":"Masson","year":"2007","journal-title":"DNA Repair"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/82818","article-title":"Passing the baton in base excision repair","volume":"7","author":"Wilson","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.freeradbiomed.2005.01.012","article-title":"Protein-protein interactions and posttranslational modifications in mammalian base excision repair","volume":"38","author":"Fan","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/MCB.01337-08","article-title":"APE1\/Ref-1 Interacts with NPM1 within Nucleoli and Plays a Role in the rRNA Quality Control Process","volume":"29","author":"Vascotto","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.3390\/ijms13066711","article-title":"8-oxoguanine DNA glycosylases: One lesion, three subfamilies","volume":"13","author":"Faucher","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrfmmm.2009.10.017","article-title":"Uracil-DNA glycosylase: Structural, thermodynamic and kinetic aspects of lesion search and recognition","volume":"685","author":"Zharkov","year":"2010","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen."},{"key":"ref_98","unstructured":"Tell, G., Lirussi, L., Antoniali, G., Wilson III, D.M., and Poletto, M. (2016). The Abasic Endonuclease APE1: Much more than a DNA Repair Enzyme. The Base Excision Repair Pathway, World Scientific."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jmb.2004.11.028","article-title":"Ape1 abasic endonuclease activity is regulated by magnesium and potassium concentrations and is robust on alternative DNA structures","volume":"345","author":"Wilson","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/379183a0","article-title":"Requirement of mammalian DNA polymerase-beta in base-excision repair","volume":"379","author":"Sobol","year":"1996","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"39095","DOI":"10.1074\/jbc.M506480200","article-title":"Long-patch base excision DNA repair of 2-deoxyribonolactone prevents the formation of DNA-protein cross-links with DNA polymerase beta","volume":"280","author":"Sung","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10408441003601836","article-title":"The relationship between cisplatin-Induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin","volume":"40","author":"Brozovic","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Gul, T., Mehraj Balkhi, H., and Haq, E. (2018). Reactive Oxygen Species (ROS). Evaluation of Cellular Processes by in Vitro Assays, Bentham Science Publishers.","DOI":"10.2174\/97816810870301180101"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Duarte, D.B., and Vasko, M.R. (2012). The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies. DNA Repair in Cancer Therapy, Elsevier.","DOI":"10.1016\/B978-0-12-384999-1.10013-7"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1124\/jpet.116.235283","article-title":"Identification and Characterization of New Chemical Entities Targeting Apurinic\/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy","volume":"359","author":"Kelley","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.dnarep.2011.06.004","article-title":"The repair function of the multifunctional DNA repair\/redox protein APE1 is neuroprotective after ionizing radiation","volume":"10","author":"Vasko","year":"2011","journal-title":"DNA Repair"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Frossi, B., Antoniali, G., Yu, K., Akhtar, N., Kaplan, M.H., Kelley, M.R., Tell, G., and Pucillo, C.E.M. (2019). Endonuclease and redox activities of human apurinic\/apyrimidinic endonuclease 1 have distinctive and essential functions in IgA class switch recombination. J. Biol. Chem., jbc.RA118.006601.","DOI":"10.1074\/jbc.RA118.006601"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.lungcan.2009.02.019","article-title":"APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells","volume":"66","author":"Wang","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Malfatti, M.C., Gerratana, L., Dalla, E., Isola, M., Damante, G., Di Loreto, C., Puglisi, F., and Tell, G. (2019). APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC. J. Exp. Clin. Cancer Res., in press.","DOI":"10.1186\/s13046-019-1294-9"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/14\/3390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:04:19Z","timestamp":1760187859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/14\/3390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":109,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["ijms20143390"],"URL":"https:\/\/doi.org\/10.3390\/ijms20143390","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]}}}